Clinical data | |
---|---|
Trade names | Temodar, Temodal, Temcad, others[1] |
Other names | TMZ |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601250 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | almost 100% |
Protein binding | 15% (10–20%) |
Metabolism | hydrolysis |
Metabolites | 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC, the active species); temozolomide acid |
Elimination half-life | 1.8 hours |
Excretion | mainly kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.158.652 |
Chemical and physical data | |
Formula | C6H6N6O2 |
Molar mass | 194.154 g·mol−1 |
3D model (JSmol) | |
Melting point | 212 °C (414 °F) (decomp.) |
| |
| |
(what is this?) (verify) |
Temozolomide, sold under the brand name Temodar among others, is an anticancer medication used to treat brain tumors such as glioblastoma and anaplastic astrocytoma.[4][5] It is taken by mouth or via intravenous infusion.[4][5]
The most common side effects with temozolomide are nausea, vomiting, constipation, loss of appetite, alopecia (hair loss), headache, fatigue, convulsions (seizures), rash, neutropenia or lymphopenia (low white-blood-cell counts), and thrombocytopenia (low blood platelet counts).[5] People receiving the solution for infusion may also have injection-site reactions, such as pain, irritation, itching, warmth, swelling and redness, as well as bruising.[5]
Temozolomide is an alkylating agent used to treat serious brain cancers; most commonly as second-line treatments for astrocytoma and as the first-line treatment for glioblastoma.[4][6][7] Olaparib in combination with temozolomide demonstrated substantial clinical activity in relapsed small cell lung cancer.[8] It is available as a generic medication.